Literature DB >> 7928000

The immunosuppressive effects of verapamil upon mitogen activated and allo-antigen inducible human cytotoxic T-lymphocytes.

B Zanker1, S Marx, T B Strom, H Köhler.   

Abstract

In this study, the effect of verapamil, a phenylalkylamine-type Ca2+ antagonist, upon the activation of human mononuclear cells was investigated and a detailed analysis of the kinetics and dose related effects of verapamil upon alloreactive cytotoxic T-cells (CTL) was undertaken. Verapamil suppressed the release of interleukin-2, proliferation and generation of CTL activity in mitogen and alloantigen stimulated human T-lymphocytes in a dose related fashion. Verapamil suppressed the steady state levels of several T-cell activation-associated gene transcripts, i.e. the mRNA encoding for interleukin-2, and a cytotoxic T-cell specific serine esterase. Verapamil exerted a novel immune-suppressive effect, i.e. the inhibition of mature alloantigen-inducible cytolytic T-cells, thus rendering verapamil a progenitor of potent and clinically useful immunosuppressive drugs.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7928000     DOI: 10.1016/0192-0561(94)90102-3

Source DB:  PubMed          Journal:  Int J Immunopharmacol        ISSN: 0192-0561


  4 in total

1.  Usefulness of targeting lymphocyte Kv1.3-channels in the treatment of respiratory diseases.

Authors:  Itsuro Kazama; Tsutomu Tamada; Masahiro Tachi
Journal:  Inflamm Res       Date:  2015-07-24       Impact factor: 4.575

2.  Novel mode of action of the calcium antagonist mibefradil (Ro 40-5967): potent immunosuppression by inhibition of T-cell infiltration through allogeneic endothelium.

Authors:  R A Blaheta; N P Hailer; N Brude; B Wittig; E Oppermann; K Leckel; S Harder; M Scholz; S Weber; A Encke; B H Markus
Journal:  Immunology       Date:  1998-06       Impact factor: 7.397

3.  The Ca2+ Channel Blocker Verapamil Inhibits the In Vitro Activation and Function of T Lymphocytes: A 2022 Reappraisal.

Authors:  José Ignacio Veytia-Bucheli; Den Alejandro Alvarado-Velázquez; Lourival Domingos Possani; Roberto González-Amaro; Yvonne Rosenstein
Journal:  Pharmaceutics       Date:  2022-07-15       Impact factor: 6.525

4.  A pilot study evaluating biomarker development for drug-induced chronic eczematous eruptions of aging individuals.

Authors:  Erika Mae Summers; Nicholas Ray Blickenstaff; Garrett Curtis Coman; Thomas Bernd Martins; Harry Raymond Hill; Richard Dennis Sontheimer
Journal:  Ann Transl Med       Date:  2017-10
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.